10-KPeriod: FY2010

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2010

Filed February 22, 2011For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) presented its 2010 annual report on Form 10-K, highlighting a year of robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company's diversified product and service offerings, including diagnostic and information technology solutions for veterinary practices, water testing, and livestock and poultry diagnostics, demonstrated resilience. IDEXX continued to invest in research and development, launching new products like the ProCyte Dx™ hematology analyzer and focusing on enhancing its integrated diagnostic solutions. The company also managed supply chain dependencies and faced competitive pressures, while navigating an evolving economic landscape. The report indicates a strong operational performance with a focus on innovation and market expansion.

Financial Highlights

50 data points
Beta

Revenue

$1.10B

52.4% Gross Margin

Net Income

$141.28M

12.8% Net Margin

EPS (Diluted)

$1.19

Total Assets

$897.14M

Cash & Equivalents

$156.91M

Free Cash Flow

$139.93M

Financial Statements
Beta
Revenue$1.10B
Cost of Revenue$524.77M
Gross Profit$578.62M
R&D Expenses$68.60M
Operating Income$203.88M
Interest Expense$2.42M
Net Income$141.28M
EPS (Basic)$1.23
EPS (Diluted)$1.19
Shares Outstanding (Basic)115.43M
Shares Outstanding (Diluted)119.12M

Key Highlights

  • 1Total revenue grew by 7.0% to $1.103 billion in 2010, with the Companion Animal Group (CAG) being the primary driver, showing 7.4% revenue growth.
  • 2The company launched its next-generation hematology analyzer, the ProCyte Dx™, in the third quarter of 2010, and saw increased sales of its Catalyst Dx® chemistry analyzer.
  • 3Reference laboratory diagnostic and consulting services within CAG experienced a significant 10.5% revenue increase, indicating strong demand for outsourced diagnostic solutions.
  • 4Practice information management systems and digital radiography within CAG saw robust growth of 15.6%, reflecting market adoption of digital imaging and software solutions.
  • 5Gross profit margin improved to 52.4% from 51.0% in the prior year, driven by operational efficiencies in manufacturing and reference laboratories.
  • 6IDEXX reported strong operating cash flow of $178.8 million, demonstrating effective cash generation from its ongoing business activities.
  • 7The company actively repurchased its own shares, with $143.1 million spent on share repurchases in 2010, underscoring a commitment to returning value to shareholders and offsetting dilution.

Frequently Asked Questions

IDEXX Laboratories operates primarily through three main business segments: the Companion Animal Group (CAG), which offers diagnostic and IT products/services for veterinary practices; Water, focusing on water quality testing products; and Livestock and Poultry Diagnostics (LPD). They also have smaller segments in Dairy and OPTI Medical (human point-of-care diagnostics).

In 2010, IDEXX reported a 7.0% increase in total revenue to $1.103 billion. Net income was $141.3 million, a significant increase from $122.2 million in 2009. The company also generated strong operating cash flow of $178.8 million.

Key risks highlighted include intense competition within its markets, dependence on a limited number of suppliers for certain critical components, potential negative impacts of a weak economy on customer spending, and regulatory compliance. The company also noted ongoing FTC and OFT investigations into its marketing and sales practices.

IDEXX's strategy focuses on developing and marketing innovative, proprietary diagnostic products and services. They aim to enhance product integration, leverage economies of scale for cost improvements, expand their market reach both domestically and internationally, and continually invest in research and development. For their CAG segment, integrating in-clinic and reference lab testing, along with practice management software, is a key differentiator.